NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

meirluc,

I believe the 17 missing SOC/placebo make it more likely that many of those 35 were censored early crossovers from after the halt that they do not want to discuss yet because of what their outcomes might imply about the ramifications of potential combo use or other. That kind of data, if brought into consideration, would have a tendency to indicate things that go beyond the scope of this trial and possibly present an absolute need for ECAs. FDA needs to be presented data that can not be used to say their hand was forced into doing something and that, I believe, may have put NWBO and it’s investors in the position we currently face. I believe that the top line data we have received falls far short of explaining critical details about this trial that are being carefully protected to prevent potential litigation of “the process” by those who are watching for any slip up they might utilize to challenge results and conclusions. Best wishes.